PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PHOSPHORUS METABOLISM”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources
PubMed1976

Changes in phosphorus metabolism during the tumor growth inhibition by metabolic acidosis.

Ammonium chloride-induced metabolic acidosis produces an increase of the phosphorus turnover rate in tumor tissue. The lower blood protein-bound 32P seems to indicate that the high phospholipid turnover observed in tumor may be related to an increased molecular degradation. It seems likely that this phenomenon together with the augmented release of phospholipid-bound calcium may induce important changes in the cell membrane behavior.

Acidosis↗
PubMedDate not supplied

[Disordered phosphorus metabolism and its correction in the acute period of severe craniocerebral trauma].

Marked hypophosphatemia was discovered in 78 patients in the acute period of severe craniocerebral injury. It led to a decrease of the level of 2,3-diphosphoglycerate (2,3 DPG) and ATP in the red cells. The reduced ATP level in the red cells was one of the causes of reduced Ca2+ ATPase activity in their membranes. Intravenous infusion of 6.8% potassium dihydrophosphate solution prevented the development of hypophosphatemia and reduction of the content of 2,3 DPG and ATP in the red cells and Ca2+ ATPase activity in their membranes, which facilitated improvement in the course of acute posttraumatic period in patients with severe craniocerebral injury and decrease of mortality.

2,3-Diphosphoglycerate↗
PubMed1984

Effects of induced total-body hyperthermia on phosphorus metabolism in humans.

The effects of total-body hyperthermia on phosphorus homeostasis are controversial. To evaluate the problem, 10 clearance studies were performed in seven patients undergoing total-body hyperthermia as an adjunct to the treatment of solid malignant tumors. Total-body hyperthermia was associated with significant reduction in plasma phosphorus concentration from a baseline value of 3.51 +/- 0.18 to 0.6 +/- 0.1 mg/dl (p less than 0.001), returning to baseline following cessation of total-body hyperthermia. The clearance of phosphorus increased from 15.2 +/- 2.5 to 26.1 +/- 3.1 ml per minute (p less than 0.01), and the fractional excretion of phosphorus increased from 11.37 +/- 2.2 to 47.68 +/- 9.7 percent (p less than 0.01). The reduction in plasma phosphorus during total-body hyperthermia was also associated with a significant reduction in the renal threshold phosphorus concentration from 3.17 +/- 0.16 to 0.38 +/- 0.08 (p less than 0.001). The changes in phosphorus homeostasis during total-body hyperthermia were independent of changes in circulating parathyroid hormone level, urinary cyclic AMP excretion, and arterial carbon dioxide tension.

Bicarbonates↗
PubMed1985

The effects of sodium fluoride, calcium phosphate, and vitamin D2 for one to two years on calcium and phosphorus metabolism in postmenopausal women with spinal crush fracture osteoporosis.

Calcium and phosphorus balances and 47Ca turnover studies were performed before and after 12-27 months of daily treatment with sodium fluoride (60 mg), calcium (30-45 mmol), phosphate (29-44 mmol), and vitamin D2 (18,000 IU) in 20 postmenopausal women with spinal crush fracture osteoporosis. Before treatment the mean calcium balance (-1.6 mmol Ca/day) was negative (P less than 0.05), whereas the mean phosphorus balance (-1.6 mmol P/day) did not differ from zero (P greater than 0.10). The treatment induced an increase in calcium absorption (P less than 0.01) with an unchanged renal excretion and dermal loss of calcium and an increase (P less than 0.02) in calcium balance, which became positive (P less than 0.01) (+3.3 mmol Ca/day). This enhancement in calcium balance was obtained by the combined effects of an increase (P less than 0.05) in bone mineralization rate and a decrease (P less than 0.05) in bone resorption rate. The observed increase in net phosphorus absorption (P less than 0.001) was more pronounced than the increase in renal excretion of phosphorus (P less than 0.001), and the phosphorus balance therefore increased (P less than 0.001) and became positive (P less than 0.001). A positive correlation was observed between net calcium and net phosphorus absorption (r = 0.065; (P less than 0.001) in the 32 studies where both calcium and phosphorus balance data were available. Furthermore, a positive correlation (r = 0.61; P less than 0.05) was found between the changes in net calcium and net phosphorus absorption during treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed2002

[Calcium-phosphorus metabolism and bone metabolism in postmenopausal patients with the thyroid gland pathology].

Bone metabolism markers (bone alkaline phosphatase, ionized calcium, inorganic phosphorus, serum osteocalcin) and urinary excretion of hydroxyproline, Ca2+ and P after overnight fasting and of creatinine were studied in 52 female patients with endemic goiter and hypothyrosis (18 of these with decompensated hypothyrosis, 34 treated with thyroid hormones) and 48 women without thyroid diseases aged 45-60 years with menopause of no longer than 10 years (6.4 +/- 0.43 years). Clinical and x-ray examinations were carried out in all women; hormonal status, basal serum levels of parathyroid hormone and calcitonin were evaluated. A trend to deceleration of bone remodeling was detected in the patients with untreated hypothyrosis in comparison with women without thyroid disease. Signs of increased bone resorption were detected in patients with endemic goiter and hypothyrosis receiving substitute hormone therapy; this gave grounds to refer patients of menopausal age with endemic goiter and hypothyrosis treated with oral thyroxin for a long time to a group at a high risk of osteoporosis and bone fractures and to start preventive osteotropic therapy from the first day of substitute thyroid hormone therapy.

Alkaline Phosphatase↗